文章名稱引用次數(shù)

• Sexualized drug use (chemsex') and high-risk sexual behaviours in HIV-positive men who have sex with men41
• Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.021
• Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics18
• Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials11
• Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 20169
• Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?9
• Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort8
• Towards person-centred care for people living with HIV: what core outcomes matter, and how might we assess them? A cross-national multi-centre qualitative study with key stakeholders8
• Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion8
• Rates of sustained virological response 12weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?8